[ARQL] ArQule, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.29 Change: 0.03 (2.38%)
Ext. hours: Change: 0 (0%)

chart ARQL

Refresh chart

Strongest Trends Summary For ARQL

ARQL is in the medium-term down -32% in 7 months. In the long-term up 214% in 2 years and down -77% below S&P in 14 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: ArQule, Inc., a clinical-stage biotechnology company, researches and develops cancer therapeutics. Its lead product candidate tivantinib is an inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase 3 clinical trial for the treatment of non-small cell lung and liver cancer; and Phase 2 clinical trial for the treatment of colorectal cancer. The company?s early clinical-stage products include ARQ 092, an inhibitor of the Akt protein kinase; ARQ 087, a multi-kinase inhibitor with pan-fibroblast growth factor receptor activity; ARQ 761, a NQ01 inhibitor; ARQ 621, an inhibitor of the Eg5 kinesin motor protein; and ARQ 736, an inhibitor of the RAF kinases. It has partnership agreement with Daiichi Sankyo Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. for implementing a clinical development program designed to realize the potential of tivantinib as a single agent; and in combination with other anti-cancer therapies in various disease indications. In addition, the company has research

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.36 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -4% Sales Growth - Q/Q-7.63% P/E-3.11
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-37.6% ROE-56.49% ROI
Current Ratio3.3 Quick Ratio Long Term Debt/Equity Debt Ratio0.45
Gross Margin Operating Margin-191.68% Net Profit Margin-183.06% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities15.23 M Cash From Operating Activities-7.55 M Gross Profit
Net Profit-4.55 M Operating Profit-4.82 M Total Assets55.32 M Total Current Assets55.08 M
Total Current Liabilities16.7 M Total Debt Total Liabilities18.5 M Total Revenue2.79 M
Technical Data
High 52 week6.81 Low 52 week1.51 Last close3.82 Last change3.8%
RSI71.07 Average true range0.32 Beta1.25 Volume304.8 K
Simple moving average 20 days25.62% Simple moving average 50 days11.76% Simple moving average 200 days-12.87%
Performance Data
Performance Week10.72% Performance Month18.63% Performance Quart-10.54% Performance Half-26.4%
Performance Year118.29% Performance Year-to-date37.91% Volatility daily7.73% Volatility weekly17.29%
Volatility monthly35.43% Volatility yearly122.75% Relative Volume733.06% Average Volume1.3 M
New High New Low

News

2019-03-15 07:00:00 | ArQule Announces Management Team Changes

2019-03-13 07:00:00 | ArQule to Present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019

2019-03-11 07:00:00 | ArQule to Participate in the 31st Annual ROTH Conference on March 17-19, 2019

2019-03-09 12:09:00 | Can Arqule Stock Continue Rocketing Higher?

2019-03-07 17:10:38 | Edited Transcript of ARQL earnings conference call or presentation 7-Mar-19 2:00pm GMT

2019-03-07 16:30:00 | Why Rosetta Stone, ArQule, and Fly Leasing Jumped Today

2019-03-07 15:37:00 | Arqule Inc ARQL Q4 2018 Earnings Conference Call Transcript

2019-03-07 13:35:00 | Here's Why ArQule Is Soaring Today

2019-03-07 07:00:00 | ArQule Reports Fourth Quarter and Full Year 2018 Financial Results

2019-03-06 13:32:18 | Is ArQule, Inc.’s NASDAQ:ARQL CEO Paid At A Competitive Rate?

2019-02-26 07:45:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Conagra Brands, Pieris Pharmaceuticals, ArQule, MoneyGram International, Internap, and TIM Participacoes S.A — New Research Emphasizes Economic Growth

2019-02-25 07:00:00 | ArQule Announces Publication of Clinical Data with Miransertib in Proteus Syndrome

2019-02-21 07:00:00 | ArQule to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019

2019-02-21 07:00:00 | ArQule to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019

2019-01-24 07:00:00 | Basilea Announces Collaboration to Study Derazantinib and Atezolizumab Tecentriq® in Urothelial Cancer

2019-01-09 07:00:00 | Basilea Announces Positive Interim Results from Registrational Phase 2 Study with Oncology Drug Candidate Derazantinib in Intrahepatic Cholangiocarcinoma iCCA

2019-01-07 08:32:53 | What You Must Know About ArQule, Inc.’s NASDAQ:ARQL Beta Value

2018-12-31 16:08:01 | Penny Stocks to Buy Using Technical Analysis for January 2019

2018-12-26 13:20:00 | 4 Pharma Stocks Heating Up On Wednesday 12/26/18

2018-12-26 07:30:00 | Biotech News Driving These Companies

2018-12-26 07:25:00 | Detailed Research: Economic Perspectives on Canopy Growth, ArQule, MoneyGram International, Teradata, Clovis Oncology, and Axovant Sciences — What Drives Growth in Today's Competitive Landscape

2018-12-24 08:58:01 | Options Traders Expect Huge Moves in ArQule ARQL Stock

2018-12-19 07:00:00 | ArQule Added to the NASDAQ Biotechnology Index

2018-12-12 00:52:56 | ArQule, Inc. ARQL: Are Hedge Funds Right About This Stock?

2018-12-03 07:00:00 | ArQule Announces Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2018 ASH Annual Meeting

2018-12-02 17:51:20 | The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

2018-11-29 07:35:00 | Recent Analysis Shows HudBay Minerals, Meridian Bioscience, ArQule, Mesoblast, Concho Resources, and Liberty Global Market Influences — Renewed Outlook, Key Drivers of Growth

2018-11-29 07:00:00 | ArQule to Host Analyst Call Highlighting Clinical Progress from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies

2018-11-21 10:57:16 | Could ArQule Inc’s NASDAQ:ARQL Investor Composition Influence The Stock Price?

2018-11-19 07:00:00 | ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 2018 American Society of Hematology ASH Annual Meeting

2018-11-16 16:01:00 | ArQule Presents Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium

2018-11-16 08:46:01 | Options Traders Expect Huge Moves in ArQule ARQL Stock

2018-11-16 08:08:31 | The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal

2018-11-14 07:00:00 | ArQule to Present at the 30th Annual Piper Jaffray Healthcare Conference on November 28, 2018

2018-11-08 07:00:00 | ArQule to Present Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium

2018-11-01 02:47:24 | ArQule ARQL Q3 2018 Earnings Conference Call Transcript

2018-10-31 22:38:58 | Edited Transcript of ARQL earnings conference call or presentation 31-Oct-18 1:00pm GMT

2018-10-31 08:15:12 | ArQule ARQL Reports Q3 Loss, Tops Revenue Estimates

2018-10-31 07:08:10 | ArQule: 3Q Earnings Snapshot

2018-10-31 07:00:00 | ArQule Reports Third Quarter 2018 Financial Results

2018-10-19 08:40:00 | New Research Coverage Highlights TIER REIT, Meridian Bioscience, ArQule, Greenlight Capital Re, ADT, and Turquoise Hill Resources — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-10-19 07:00:00 | ArQule Presents Orphan Disease Clinical Data at the American Society of Human Genetics ASHG 2018 Annual Meeting for Its pan-AKT Inhibitor, Miransertib ARQ 092

2018-10-17 08:15:53 | The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise

2018-10-17 07:00:00 | ArQule to Report Third Quarter 2018 Financial Results on October 31, 2018

2018-10-14 13:21:15 | The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs

2018-10-04 16:01:00 | ArQule to Present Clinical Update for Miransertib in Rare Disease at the American Society of Human Genetics ASHG 2018 Annual Meeting

2018-09-24 07:00:00 | ArQule to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on October 2, 2018

2018-09-24 07:00:00 | ArQule to Present at the Cantor Global Healthcare Conference on October 1, 2018

2018-09-19 13:11:01 | ArQule Inc NASDAQ:ARQL Is Expected To Breakeven

2018-09-13 07:00:00 | Miransertib ARQ 092 Granted Fast Track Designation for the Treatment of PIK3CA-Related Overgrowth Spectrum PROS